52nd week of 2019 patent applcation highlights part 9 |
Patent application number | Title | Published |
20190388460 | ANTIMICROBIAL GUANIDINIUM MACROMOLECULES WITH BACTERIA TARGETING MOIETIES - Compositions and methods regarding antimicrobial guanidinium macromolecules with one or more targeting moieties for selectively targeting bacteria are provided. According to an embodiment, an antimicrobial macromolecule is provided that comprises a polymer backbone and one or more guanidinium moieties that extend from the polymer backbone. The antimicrobial macromolecule further comprises a targeting moiety that extends from the polymer backbone. The targeting moiety can comprise a substance favored for consumption by bacteria, such as a monosaccharide. | 2019-12-26 |
20190388461 | TOPICAL COMPOSITIONS AND METHODS OF USING THE SAME - The present invention generally relates to topical compositions and methods of using the same. The topical compositions may comprise a hydrophilic composition and a hydrophobic composition in admixture. The hydrophobic composition may include a nitric oxide-releasing compound such as, for example, a diazeniumdiolate functionalized co-condensed silica particle. In some embodiments, the topical composition may be self-emulsifying. Further described herein are kits comprising a hydrophilic composition and a hydrophobic composition. | 2019-12-26 |
20190388462 | Composition for treatment or prevention of age-related macular degeneration comprising molecular hydrogen - The present application provides a composition for treatment or prophylaxis of age-related macular degeneration in a subject, comprising molecular hydrogen as an active ingredient, and a method for treatment or prophylaxis of age-related macular degeneration, comprising administering the composition to a subject with age-related macular degeneration. | 2019-12-26 |
20190388463 | Pharmaceutical Composition for Treating Cancer Comprising Trypsinogen and/or Chymotrypsinogen and an Active Agent Selected from a Selenium Compound, a Vanilloid Compound and a Cytoplasmic Glycolysis Reduction Agent - The present invention generally relates to pharmaceutical compositions containing a protease proenzyme and use thereof for treating cancer. The pharmaceutical compositions are directed to compositions comprising a protease proenzyme and an active agent, the composition being capable of providing a multi-functional approach for treating cancer. The pharmaceutical compositions are also directed to compositions comprising a first and a second protease proenzyme capable of activation at or near a surface of a tumour cell to enhance cell-to-cell adhesion of tumour cells, effect proteolysis of tumour cells, or induce tumour cell apoptosis, differentiation or immunorecognition, wherein the first protease proenzyme is chymotrypsinogen and the second protease proenzyme is trypsinogen. The pharmaceutical compositions are also directed to compositions comprising a first and second active agent each capable of inducing intracellular activity in tumour cells. | 2019-12-26 |
20190388464 | IRON-FORTIFIED FOOD COMPOSITION - The present invention relates to compositions for fortifying food and/or beverages with iron. More specifically, the present invention relates to compositions comprising Fe(lll), phytic acid, a hydrolysed protein and an acidity regulator, which provide stable and soluble sources of iron for fortifying food and/or beverages. | 2019-12-26 |
20190388465 | METHODS OF INHIBITING MICROBIAL INFECTIONS USING ZINC-CONTAINING COMPOSITIONS - Methods of inhibiting and/or reducing the occurrences and/or duration of microbial infections, such as rhinovirus and influenza infections, are provided herein. The methods comprise delivering an oral composition comprising at least one E | 2019-12-26 |
20190388466 | SILICONE MATERIALS HAVING ANTIMICROBIAL EFFICIENCY - Disclosed are antimicrobial silicone substances, which are obtained by using multifunctional cellulose/silver and silicon matrix nanocomposites. Using environmentally friendly, simple deposition techniques, Ag particles were deposited on cellulose. Silicone was filled with the obtained composites of cellulose and silver particles. The created modified cellulose/silver and silicone composite is characterized by good physical and chemical properties, as well as strong antimicrobial effect on both Gram-positive and Gram-negative bacteria. | 2019-12-26 |
20190388467 | METHODS FOR MANAGING ADVERSE EVENTS IN PATIENT POPULATIONS REQUIRING TRANSFUSION - Method for transfusion medicine to reduce adverse events in transfusion patient populations based on underlying patient physiology. | 2019-12-26 |
20190388468 | IMMUNE CELLS EXPRESSING AN ANTIGEN BINDING RECEPTOR AND A CHIMERIC COSTIMULATORY RECEPTOR - The present invention provides an immune effector cell that comprises a chimeric antigen receptor (CAR) specific for a tag of a tagged polypeptide, wherein said polypeptide binds to an antigen of a target cell, and a chimeric costimulatory receptor (CCR) specific for a further antigen. The CCR is not able to mediate said immune response on its own but boosts the immune response of said immune effector cell triggered by the CAR. | 2019-12-26 |
20190388469 | PROTEIN DELIVERY IN PRIMARY HEMATOPOIETIC CELLS - Methods and compositions are provided for highly efficient delivery of Cas9 and Cas9 ribonucleoproteins to cells, including primary hematopoietic cells and primary hematopoietic stem cells. | 2019-12-26 |
20190388470 | NUCLEIC ACID CONSTRUCTS COMPRISING GENE EDITING MULTI-SITES AND USES THEREOF - Disclosed herein is a polynucleotide construct comprising one or more nuclease recognition sequences upstream and downstream of a Gene editing multi-site that comprises a plurality of nuclease recognition sequences. The plurality of nuclease recognition sequences facilitate insertion of one or more exogenous donor genes into the host cell. | 2019-12-26 |
20190388471 | TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR - The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein. | 2019-12-26 |
20190388472 | CAR+ T CELLS GENETICALLY MODIFIED TO ELIMINATE EXPRESSION OF T-CELL RECEPTOR AND/OR HLA - The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising disrupted T cell receptor and/or HLA and comprising a chimeric antigen receptor. In certain embodiments, the compositions are employed allogeneically as universal reagents for “off-the-shelf” treatment of medical conditions such as cancer, autoimmunity, and infection. In particular embodiments, the T cell receptor-negative and/or HLA-negative T cells are generated using zinc finger nucleases, for example. | 2019-12-26 |
20190388473 | METHODS AND COMPOSITIONS FOR IMMUNOMODULATION - Provided are cells containing exogenous antigen and uses thereof. | 2019-12-26 |
20190388474 | ENCAPSULATED DIAGNOSTICS AND THERAPEUTICS IN NANOPARTICLES - CONJUGATED TO TROPIC CELLS AND METHODS FOR THEIR USE - A therapeutic or diagnostic delivery vehicle is provided. The delivery vehicle may include one or more particles, such as microparticles, nanoparticles and stimuli-responsive particles, conjugated to a tropic cell that targets at least one pathological entity or site. In addition. a pharmaceutical composition is provided. The pharmaceutical composition may include, among other things, a particle conjugated to a tropic cell such as those discussed above and at least one diagnostic or therapeutic agent, such as those described herein. In some aspects, the tropic cell may target at least one pathological entity or site. Further, methods for diagnosing, monitoring or treating a pathological condition in a subject are provided. Such methods may include administering a therapeutically effective amount of the pharmaceutical composition to a subject. | 2019-12-26 |
20190388475 | STEM CELL MICROPARTICLES - This invention relates to stem cell microparticles, their use and production, in particular neural stem cell microparticles and their use in therapy. The stem cell microparticle is typically an exosome or microvesicle and may be derived from a neural stem cell line. The neural stem cell line may be a conditionally-immortalised stem cell line such as CTXOE03 (deposited at the ECACC with Accession No. 04091601). | 2019-12-26 |
20190388476 | COMPOSITIONS AND METHODS FOR TREATING AND REPAIRING TENDONS - The present invention relates to compositions and methods utilizing hair follicle derived Non-Bulbar Dermal Sheath cells for use in the treatment or prevention of the tendon injuries. | 2019-12-26 |
20190388477 | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PROPHYLAXIS OF A PERFUSION DISORDER - The present disclosure provides compositions and methods for the treatment or prophylaxis of a perfusion disorder, such as ischemia and/or reperfusion injury, in a subject's organ, tissue or extremity by preserving or improving endothelial function, reducing vascular injury, and/or promoting vascular repair. The disclosed compositions comprise endothelial colony-forming cells or a serum-free composition comprising chemically defined media conditioned by endothelial colony-forming cells. | 2019-12-26 |
20190388478 | USE OF PLACENTAL STEM CELLS IN TREATMENT OF ACUTE KIDNEY INJURY - Provided herein are methods of using human placental stem cells in the treatment of subjects having acute kidney injury (AKI). | 2019-12-26 |
20190388479 | NANO-VESICLES DERIVED FROM GENUS MICROCOCCUS BACTERIA AND USE THEREOF - Provided are vesicles derived from bacteria belonging to the genus | 2019-12-26 |
20190388480 | Method of Increasing Probiotic Viability in Food Products - A pre-conditioned probiotic composition and method of forming the pre-conditioned probiotic composition comprises introducing thawed probiotic cells into a pre-conditioning environment having sufficient nutrients and conditions to prepare the thawed probiotic cells for surviving and successfully thriving in a targeted food product. Thawed probiotic cells are then provided with an incubation period of at least 2 hours to produce inoculation pre-treated probiotic cells with improved shelf life in a food product. | 2019-12-26 |
20190388481 | REGULATE GUT MICROBIOTA TO TREAT NEURODEGENERATIVE DISORDERS - Disclosed herein are methods and compositions that can be used to improve motor deficits and neuroinflammation in subjects in need, for example subjects suffering from neurodegenerative disorders (e.g., Parkinson's disease). Also disclosed are methods and compositions that can be used to diagnose neurodegenerative disorders, such as Parkinson's disease. | 2019-12-26 |
20190388482 | Compositions and Methods for Detecting and Treating Brain Injury Associated Fatigue and Altered Cognition (BIAFAC) - The present invention includes composition, methods and kits for detecting and treating brain injury associated fatigue or altered cognition (BIAFAC) in a human patient comprising: identifying a human patient in need of treatment for brain injury associated fatigue or altered cognition associated with an altered intestinal flora; and providing the human patient with a composition comprising at least one of: a | 2019-12-26 |
20190388483 | DEVELOPMENT OF NEW MONOCLONAL ANTIBODIES RECOGNIZING HUMAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) - Provided herein are compositions and methods for the inhibition of enteric infection. In particular, compositions comprising bacteria of the class Clostridia are administered to human and/or animal subjects to prevent or decrease susceptibility to enteric infection. | 2019-12-26 |
20190388484 | LACTOBACILLUS REUTERI GMNL-263 FOR IMPROVING HYPERTENSION AND ITS COMPOSITIONS THEREOF - Present invention discloses a | 2019-12-26 |
20190388485 | PROBIOTICS FOR USE AS ANTI-INFLAMMATORY AGENTS IN THE ORAL CAVITY - The present invention relates to certain microorganisms or mixtures thereof for use in the treatment and/or prevention of inflammation in the oral cavity, in particular for use in the treatment and/or prevention of dental caries and/or periodontal disease. | 2019-12-26 |
20190388486 | METHODS OF ENHANCING THE POTENCY OF INCRETIN-BASED DRUGS IN SUBJECTS IN NEED THEREOF - The present invention relates to methods of enhancing the potency of incretin-based drugs in subjects in need thereof. Through different animal models, the inventors identified that a specific gut microbiota signature impairs GLP-1-activated gut-brain axis which could be transferred to germ free mice. The dysbiotic gut microbiota induces enteric neuropathy, reduces GLP-1 receptor and nNOS mRNA concentration, GLP-1-induced nitric oxide production for the control of insulin secretion and gastric emptying. The frequency of | 2019-12-26 |
20190388487 | DETARGETED ADENOVIRUS VARIANTS AND RELATED METHODS - The present disclosure describes the generation and the use of Ad variants (Ad) possessing any combination of mutations in genes that code for the hexon, penton, fiber, and non-structural proteins, where simultaneous modification of hexon and penton are made to avoid the trapping of Ad in the liver and to reduce toxicity after intravascular virus administration. Such liver de-targeted Ad can be useful tool for selective and specific gene delivery to extra-hepatic tissues and cells, including disseminated metastatic cancer cells. | 2019-12-26 |
20190388488 | ANTICANCER COMPOSITION COMPRISING TUMOR-SPECIFIC ONCOLYTIC ADENOVIRUS AND IMMUNE CHECKPOINT INHIBITOR - The present invention relates to an anticancer composition comprising a tumor-specific oncolytic adenovirus and an immune checkpoint inhibitor. The recombinant adenovirus having IL-12 and shVEGF, or IL-12 and GM-CSF-RLX inserted therein, according to the present invention, exhibits an excellent anticancer effect by enhancing immune functions, and such anticancer effect has been confirmed to be notably enhanced through concomitant administration with an immune checkpoint inhibitor, and thus the present invention may be used as a key technique in the field of cancer treatment. | 2019-12-26 |
20190388489 | COMBRETUM LAURIFOLIUM MART. EXTRACT AND METHODS OF EXTRACTING AND USING SUCH EXTRACT - A method of inhibiting COX-2, inhibiting NF-Kappa B activation, treating inflammation, or treating cancer may comprise administering a therapeutically effective amount of an extract of | 2019-12-26 |
20190388490 | PLANT EXTRACTIONS, COMPOSITIONS CONTAINING SAME, AND USES THEREOF - This disclosure relates to plant extracts selected from | 2019-12-26 |
20190388491 | ANTI-FATIGUE FOOD COMPOSITION AND ANTI-FATIGUE AGENT - Problems To provide an anti-fatigue food composition exerting an anti-fatigue effect in the form of food to be ingested easily. | 2019-12-26 |
20190388492 | METHODS FOR PREVENTION AND TREATMENT OF ACUTE RENAL INJURY - The disclosure relates to a method for protecting a kidney from renal injury. For example, acute renal injury may be associated with decreased or blocked blood flow in the subject's kidney or exposure to a nephrotoxic agent, such as a radiocontrast dye. The methods include administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof. | 2019-12-26 |
20190388493 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF FRIEDREICH'S ATAXIA - The disclosure provides methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia, and/or reducing the likelihood or severity of Friedreich's ataxia. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to e.g., reduce oxidative stress, increase mitochondrial metabolism, or a combination thereof. | 2019-12-26 |
20190388494 | THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS - There are disclosed therapeutic combinations of an antibacterial peptide and an antibiotic drug for use in the treatment of infections caused by Gram-negative pathogens, including bacterial strains resistant to common antibiotics. Also disclosed are pharmaceutical preparations and compositions containing the antibacterial peptide and antibiotics. | 2019-12-26 |
20190388495 | Pharmaceutical Composition for Preventing or Treating Hypersensitivity Immune Disease, and Method for Producing Same - The present invention relates to a production method of a composition that can prevent, ameliorate, or treat hypersensitivity immune diseases including allergic diseases, and the composition produced by the method. In the method, the plasmacytoid dendritic cells with tolerogenic capacity may be induced from the immature dendritic cells at a high yield using a simple and easy process. The plasmacytoid dendritic cells can effectively prevent, ameliorate or treat the hypersensitivity immune diseases. | 2019-12-26 |
20190388496 | ANG (1-7) DERVIATIVE OLIGOPEPTIDES FOR THE TREATMENT OF PAIN - The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and pain. | 2019-12-26 |
20190388497 | NOVEL COMPOUNDS (IMMUNORHELINS - INTRACELLULAR INFECTIONS) - The present invention provides immune stimulating peptides (immunorhelins) capable of activating GnRH receptors when administered to animal or human patients or cells. These immunorhelins have utility in treating intracellular bacterial, fungal, and protozoal infections. | 2019-12-26 |
20190388498 | READY-TO-USE OXYTOCIN FORMULATION AND USES THEREOF - A read-to-use high concentration oxytocin formulation that is free of chlorobutanol. | 2019-12-26 |
20190388499 | MACROCYCLIC PEPTIDES TO DECREASE C-MYC PROTEIN LEVELS AND REDUCE CANCER CELL GROWTH - The present technology provides methods and medicaments useful for treating prostate cancer and breast cancer. Such methods include administering at least one of cyclo[Phe-D-Pro-Phe-Trp] and cyclo[Phe-D-Pro-Phe-D-Trp] to a subject suffering from prostate cancer or breast cancer. | 2019-12-26 |
20190388500 | DELIVERY OF DRY FORMULATIONS OF OCTREOTIDE - Methods and devices are described for delivering octreotide to a patient, comprising implanting a controlled release composition for delivering octreotide, wherein the composition does not require hydration prior to implantation, and wherein the composition optionally comprises a release agent. | 2019-12-26 |
20190388501 | Glycopeptide Derivatives For Use In The Treatment And/Or Prevention And/Or Attenuation of Fibrosis Diseases - The present invention relates to a compound of the following formula (I), as well as to a pharmaceutical composition comprising at least one compound of following formula (I) and at least one pharmaceutically acceptable excipient, for use in the treatment and/or prevention and/or attenuation of fibrosis diseases, in particular excessive scars such as keloids or hypertrophic scars. | 2019-12-26 |
20190388502 | GIP/GLP1 AGONIST COMPOSITIONS - A composition of tirzepatide, comprising an agent selected from NaCl and propylene glycol; and dibasic sodium phosphate is provided. | 2019-12-26 |
20190388503 | FORMULATION, DOSAGE FORM AND METHOD OF REDUCING KNEE PAIN - An injectable aqueous formulation as well as a dosage form is disclosed for use in intra-articular injection of a specific peptide of SEQ ID NO: 1, whereby the joint pain at the injection site is relieved in the absence of detectable changes in joint cartilage formation, with pain particularly relieved under certain stress motions such as walking down stairs. | 2019-12-26 |
20190388504 | CAPCNA PEPTIDE THERAPEUTICS FOR CANCER - Administration of compositions comprising cell-permeable cancer-specific proliferating cell nuclear antigen derived peptides and their variants reduces the proliferation of cancer cells and also augments cytotoxic effects of chemotherapeutics. The compositions are effective in cells harboring mutations in DNA repair proteins. | 2019-12-26 |
20190388505 | METHODS AND COMPOSITIONS FOR IMMUNOMODULATION - The methods and uses described herein relate to the modulation of the immune system by modulation of Sema3F levels and/or activity, e.g. suppressing allograft rejection or inflammation by administering a Sema3F agonist or increasing an immune response by administering a Sema3F inhibitor. | 2019-12-26 |
20190388506 | FACTOR H FRAGMENT FOR USE AS AN ANTI-ANGIOGENIC AGENT - The invention relates to a complement factor H fragment for use in the treatment and/or prophylaxis of a disease involving neovascularization. | 2019-12-26 |
20190388507 | TREATING NEURODEGENERATIVE DISEASES WITH PROGRANULIN - The invention relates to methods and compositions for treating a neurodegenerative disease. More particularly, the present invention is directed to methods of treatment of neurodegenerative diseases using progranulin and progranulin polypeptides, and methods of treatment of neurodegenerative diseases using effectors, or combinations of effectors, that modify progranulin expression. | 2019-12-26 |
20190388508 | PROGRANULIN AND PROGRANULIN DERIVATIVES IN TREATING IMPAIRED FRACTURE HEALING - About 5-10% of all fractures result in delayed or impaired healing. Impaired bone fracture is difficult for the patient, and is very expensive for the medical system. The present disclosure provides methods of treating impaired bone fracture healing comprising administration of an effective amount of progranulin or progranulin derivatives to a subject suffering from delayed or impaired bone fracture healing. The disclosure also provides medical compositions and formulations comprising progranulin or progranulin derivatives to be used in the treatment of impaired bone fracture healing. | 2019-12-26 |
20190388509 | METHOD OF DELIVERING GONADOTROPIN RELEASING HORMONE OR AN ANALOGUE THEREOF INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE - Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract. | 2019-12-26 |
20190388510 | GLUCAGON-T3 CONJUGATES - Provided herein are glucagon agonist peptides conjugated with thyroid hormone receptor ligands that are capable of acting at the thyroid hormone receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes, obesity, metabolic syndrome and chronic cardiovascular disease, comprising administering the conjugates of the invention. | 2019-12-26 |
20190388511 | Long-Acting Formulations of Insulin - The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine. | 2019-12-26 |
20190388512 | DEVICE FOR TITRATING BASAL INSULIN - The invention relates to a novel administration regime useful in the treatment of diseases or conditions where administration of insulin will be of benefit. In particular, the invention relates to a long-acting or ultra-long acting insulin for use in treating a disease or condition where administration of insulin will be of benefit, wherein the administration of said insulin includes or consists of one or more of the following steps: (a) obtaining a first data set of the subject, (b) obtaining a second data set of the subject, (c) obtaining a first data structure of the subject, and (d) obtaining a second data structure of the subject. When a determination is made that the at least first data structure, second data structure, first data set, and second data set collectively do contain the set of evaluation information, the device further includes providing the long-acting or ultra-long-acting insulin dose guidance recommendation. | 2019-12-26 |
20190388513 | OIL BASED FORMULATIONS FOR SUBLINGUAL AND BUCCAL DELIVERY - The present invention is a delivery system for sublingual and/or buccal delivery comprising at least one functional oil (i.e. acting as an oil delivery base); at least one surfactant; and at least one pharmaceutically active agent. The invention also includes a method for treating diabetes, for regulating blood glucose levels and/or for treating hyperglycaemia by sublingual or buccal administration of the delivery system where the pharmaceutical agent is insulin and/or an insulin analogue or mimetic, and/or a glucagon-like peptide-1 agonist. | 2019-12-26 |
20190388514 | HIGH-PURITY INHALABLE PARTICLES OF INSULIN AND INSULIN ANALOGUES, AND HIGH-EFFICIENCY METHODS OF MANUFACTURING THE SAME - A high-purity inhalable insulin material, used for preparing a pulmonary pharmaceutical product, includes insulin particles having a particle size at the micrometer level and having the following characteristics: (i) the purity of insulin is not less than 96% on the dried basis; (ii) the total amount of insulin-related impurities is not more than 2%; (iii) the total amount of solvent impurities, which is not a co-solvent formulation component for a pulmonary product, is not more than 0.03%; and (iv) the total amount of non-solvent impurities is not more than 0.3%. Up to 99% by volume of the insulin particles in the inhalable insulin have a particle size of less than 5 μm, based on the total volume of the insulin particles. A high-efficiency method prepares high-purity inhalable insulin material. The yield rate for the high-efficiency method is 75 to 85% or more. | 2019-12-26 |
20190388515 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN THE PI OF WHICH IS FROM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS - Described are physically stable compositions in the form of an injectable aqueous solution, the pH of which is from 6.0 to 8.0, comprising at least a basal insulin of which the isoelectric point (pI) is from 5.8 to 8.5, and a co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical. | 2019-12-26 |
20190388516 | HEMOSTATIC PRODUCTS - A hemostatic product that includes a dry fibrinogen mixture, a dry thrombin mixture and a biologically tolerable liquid. The dry fibrinogen mixture includes fibrinogen and at least one fibrinogen stabilizer. The dry thrombin mixture includes thrombin and at least one thrombin stabilizer. The biologically tolerable liquid is mixed with the dry fibrinogen mixture and the dry thrombin mixture to form the hemostatic product. | 2019-12-26 |
20190388517 | Biomaterial Devices and Topical Compositions for Treatment of Skin Abnormalities - Devices for guided tissue regeneration (GTR) include a matrix of chitosan and mutable collagenous tissue (MCT) wherein the chitosan is electrostatically bonded to the MCT to form MCT-chitosan composite material. The MCT can be isolated from invertebrate marine organisms, such as sponges, jellyfish, mollusks and echinoderms. The MCT-chitosan composite material can be formulated as a biofilm, a 3D-sponge, a hydrogel, or as an electrospun nanofiber, or the MCT-chitosan composite material can coat a biomaterial surface. The devices can include wound dressings and tissue sponges, including 3D sponges. Applications include tissue engineering and wound healing, as well as burns and other related guided tissue regeneration applications. MCT and MCT-chitosan composite material, contained in a pharmaceutically acceptable topical carrier, also has cosmeceutical applications, for treating scars, as well as skin discoloration and various pigmentation issues, including melasma/chloasma. | 2019-12-26 |
20190388518 | Formulations for Nutritional Support in Subjects in Need Thereof - Formulations having a protein component, in which the protein contains one or more digestion-aiding proteins, and one or more immunoprotective proteins. The ratio by weight of the one or digestion-aiding proteins to the one or more immunoprotective proteins may be about 12:1 to about 1:1. The formulations may also contain a fat component, a carbohydrate component, and vitamins and minerals. These formulations can be used to provide nutritional support to a subject, either as dietary supplements or as a primary source of nutrition, such as for an infant formula. The formulations may also be used to promote or induce proliferation of intestinal cells, promote or induce differentiation of intestinal cells, prevent or inhibit growth of enteropathogenic | 2019-12-26 |
20190388519 | USE OF PHOSPHORYLATED TAU AND P38GAMMA TO TREAT A NEUROLOGICAL CONDITION - The present invention relates to a method of treating or preventing a neurological condition mediated by a tau-dependent signalling complex in neurons of a subject, comprising treating the subject to: (a) promote phosphorylation of one or more amino acids residues of tau, wherein the phosphorylation of the amino acid residues causes disruption of the tau-dependent signalling complex in neurons of the subject; or (b) introduce a variant of tau that causes disruption of the tau-dependent signalling complex in neurons of the subject. The invention also relates to vectors, compositions and kits for treating or preventing a neurological condition mediated by a tau-dependent signalling complex in neurons of a subject. | 2019-12-26 |
20190388520 | Compositions and Methods for Oral Delivery of Therapeutic Cargo - The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders. The present disclosure relates to a non-toxic mutant form of the | 2019-12-26 |
20190388521 | REDUCTION OF EGFR THERAPEUTIC TOXICITY - In certain embodiments, the present invention provides a method of treating a subject having a tumor that expresses EGFR and/or uPAR, even if at low levels. In certain embodiments, the present invention provides a method of preventing hemangiosarcoma (HSA) in a dog predisposed to developing HSA or angiosarcoma in a human predisposed to developing angiosarcoma. In certain embodiments, the present invention provides a method of preventing a hemangiosarcoma (HSA) in a dog that is positive for HSA by means of a blood test but negative by tumor imaging. | 2019-12-26 |
20190388522 | METHODS FOR TREATING DISORDERS ASSOCIATED WITH ANGIOGENESIS AND NEOVASCULARIZATION - Provided herein are methods and compositions for the treatment of diseases associated with angiogenesis and neovascularization. In one aspect, the invention relates to a method for treating a condition in an eye of a patient in need thereof comprising administering to the patient in multiple dosing sessions, an effective amount of an immunoconjugate dimer, wherein the monomer subunits of the dimer each comprises a mutated human factor VIIa (fVIIa) protein conjugated to the human immunoglobulin G1 (IgG1) Fc domain and a VEGF inhibitor, wherein the administration results in an improved outcome compared to a patient having been administered the VEGF inhibitor alone. | 2019-12-26 |
20190388523 | FACTOR IX GENE THERAPY - The invention relates to a new, more potent, coagulation Factor IX (FIX) expression cassette for gene therapy of Haemophilia B (HB). Disclosed is a vector for expressing factor IX protein, the vector comprising a promoter, a nucleotide sequence encoding for a functional factor IX protein, and an intron sequence, wherein the intron sequence is positioned between exon 1 and exon 2 of the nucleotide sequence encoding for a functional factor IX protein, and wherein the intron sequence has at least 80% identity to the sequence of SEQ ID NO. 1 as disclosed herein. | 2019-12-26 |
20190388524 | TREATMENT AND DETECTION OF TRYPANOSOMES - The present invention relates to methods and compositions for preventing, treating and diagnosing infection by trypanosomes. The invention also relates to the use of excreted/secreted antigens (exoantigens, secretome) and specifically to the identification of a protein excreted/secreted by the trypanosomes, the inhibition of which makes it possible to provide effective protection, mainly by vaccination, against infection by trypanosomes or the development or spread thereof. The invention relates to use of the protein, the derivatives thereof, a nucleotide sequence derived from said protein, or an extract enriched with said protein, and to the use of antibodies directed against said trypanosomes for immunotherapy, diagnosis, and monitoring of infections by trypanosomes. | 2019-12-26 |
20190388525 | BCMA CHIMERIC ANTIGEN RECEPTORS - The invention provides improved compositions for adoptive T cell therapies for B cell related conditions. | 2019-12-26 |
20190388526 | BCMA CHIMERIC ANTIGEN RECEPTORS - The invention provides improved compositions for adoptive T cell therapies for B cell related conditions. | 2019-12-26 |
20190388527 | BCMA CHIMERIC ANTIGEN RECEPTORS - The invention provides improved compositions for adoptive T cell therapies for B cell related conditions. | 2019-12-26 |
20190388528 | BCMA CHIMERIC ANTIGEN RECEPTORS - The invention provides improved compositions for adoptive T cell therapies for B cell related conditions. | 2019-12-26 |
20190388529 | CANCER VACCINE COMPOSITION - A cancer vaccine composition for human leukocyte antigen (HLA)-A*0206-positive persons, comprising a protein product of the tumor suppressor gene WT1 or a partial peptide thereof. | 2019-12-26 |
20190388530 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2019-12-26 |
20190388531 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2019-12-26 |
20190388532 | Immunogenic Compounds For Cancer Therapy - The invention relates to an immunogenic compound comprising an antigenic peptide having amino acid similarity with a tumor antigen, which antigenic peptide is selected in the group consisting of peptides having amino acid similarity with IL13RA2, the said antigenic peptide being selected in the group consisting of sequences described in the specification. | 2019-12-26 |
20190388533 | PORCINE CIRCOVIRUS TYPE 3 STRAIN, VACCINE COMPOSITION, METHOD OF MAKING THE SAME AND USE THEREOF - The disclosure relates to a porcine circovirus type 3 virus strain, and a vaccine composition prepared from the immunogenic substance of the strain, the porcine circovirus type 3 virus strain has good immunogenicity, and the prepared vaccine composition can provide complete protection against varies of porcine circovirus type 3 viruses from different sources. | 2019-12-26 |
20190388534 | INFLUENZA VACCINE - The present invention relates to a composition comprising at least one ISCOM complex and at least one ectodomain from at least one hemagglutinin (HA) domain and at least one ectodomain from at least one neuraminidase (NA) domain from one or lore influenza virus, wherein the extodomains represent ectodomains isolated from the influenza virus. The invention also regards a kit. The composition may be used as an immune stimulating medicine, immune modulating pharmaceutical or a vaccine e.g. against influenza for vertebrates, e.g. birds and mammals. | 2019-12-26 |
20190388535 | BACULOVIRUS AND COMPOSITION FOR DETECTION AND PREVENTING OF PORCINE EPIDEMIC DIARRHEA VIRUS INFECTION - A baculovirus displaying a porcine epidemic diarrhea virus S protein or S1 domain thereof is provided for preventing porcine epidemic diarrhea virus infection. | 2019-12-26 |
20190388536 | Human Type 14 Replication Defective Adenovirus Vector and Preparation Method for Same and Applications Thereof - The present invention provides a human type 14 replication defective adenovirus vector, and a preparation method for the same, the method comprising: constructing an Ad14 genome into a plasmid, with knocking out E3 and E1 genes of the Ad14 genome, and replacing open reading frames 2, 3, 4, 6, and 6/7 of an E4 gene of the Ad14 genome with corresponding reading frames of an Ad5 genome. The human type 14 replication defective adenovirus vector according to the present invention is potentially applicable in the research and development of a vaccine and a drug against human type 14 adenovirus infection, applicable as a gene vector in the research and development of other pathogen vaccines, and applicable in a biological report and trace system, etc. | 2019-12-26 |
20190388537 | PROCESS FOR PREPARING PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATES - An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of | 2019-12-26 |
20190388538 | INCREASED FERTILITY IN BOVINE SPECIES - The present invention relates to compositions and methods for immunomodulation which are effective for increasing conception rate in cows. | 2019-12-26 |
20190388539 | METHOD OF MANUFACTURING VEGF ANTAGONIST FUSION PROTEINS - Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4. | 2019-12-26 |
20190388540 | HER3 INHIBITOR FOR MODULATING RADIOSENSITIVITY - The present invention relates to the use of an inhibitor of HER-3 for the treatment of a hyperproliferative disease in combination with radiation treatment. | 2019-12-26 |
20190388541 | MAGNETIC NANOPARTICLE DELIVERY SYSTEM FOR PAIN THERAPY - Embodiments disclosed herein relate to magnetic nanoparticles having a non-narcotic analgesic, as well as methods of preparation and use thereof. A magnetically response pharmaceutical can include a core region having magnetic nanoparticles (MNPs) and a protein-based analgesic. Further, an exterior coating comprising a polymer can be formed around the core region. The magnetically responsive pharmaceutical can be administered to a recipient and directed to a target region using an external magnetic field. | 2019-12-26 |
20190388542 | DELIVERY OF THERAPEUTIC COMPOUNDS WITH IRON OXIDE NANOPARTICLES - The present invention relates to the field of drug delivery, in particular the delivery of unmodified cargo molecules (such as doxorubicin and Taxol©) using iron oxide nanoparticles as therapeutic delivery agents. Specifically described are methods to entrap cargo (i.e. known therapeutics (drugs) and other types of molecules) into the exterior coating of iron oxide nanoparticles, including iron oxide nanoparticles approved for use in humans. Additionally, methods describe the use of such drug-loaded nanoparticles as therapeutic delivery agents. Further, methods include quantifying and visualizing the amount of cargo molecule loading levels when preparing these therapeutic agents and then quantifying and visualizing the amount of delivery (i.e. unloading) of these cargo molecules from these nanoparticles using compact magnetic relaxometers, common NMR instruments and magnetic resonance imaging (MRI) instruments. | 2019-12-26 |
20190388543 | FORMULATIONS AND METHODS FOR COMPOSITIONS USED IN WEARABLE DRUG DELIVERY DEVICES - Formulations for topical compositions which may be used to deliver drugs. The formulations may be used with a wearable drug delivery device for transdermal delivery. The composition may comprise a clay carrier such as kaolin and/or halloysite, loaded with one or more target compositions. The composition may comprise about 5 to about 15 percent by weight kaolin; about 5 to about 15 percent by weight oil carrier; about 2 to about 3 percent by weight essential oil; about 6.5 to about 26 percent by weight emollient; about 15 to about 20 percent by weight aloe vera barbadensis juice gel; about 0.9 percent to about 5 percent by weight thickening agent; about 0.1 percent to about 5 percent by weight stabilizer; about 2 percent to about 8 percent by weight surfactant; about less than 1 percent by weight target compound; about 0.35 to about 1.8 percent by weight preservative; and about 1 percent to about 5 percent by weight water. | 2019-12-26 |
20190388544 | Composition for Patch Preparation Comprising Drug, Organic Solvent, Lipophilic Mass Base, and Powder - The object of the present invention is to provide a composition for a non-aqueous patch preparation with excellent adhesibility which can sustainedly release a drug. The patch preparation of the present invention can improve the adhesibility of the patch preparation and the release property of a drug by the addition of a powder ingredient (a filler or the like). As a result, the long-time sustention of the adhesibility of tape preparations enables an improvement of the transdermal absorbability and the sustained release of a drug. By the use of a composition for a patch preparation comprising this powder ingredient, a drug, regardless of the type of a drug is dissolved in an organic solvent or an ionic liquid to prepare a drug solution comprising the organic solvent, the drug solution is incorporated into the non-aqueous patch preparation of the present invention, and thereby a preparation with the improved transdermal absorbability and the improved sustained release can prepared. | 2019-12-26 |
20190388545 | IONIC LIQUIDS FOR TRANSDERMAL DRUG DELIVERY - The compositions and methods described herein are topically applied to the skin with negligible or no skin irritation and can direct or prevent transport through the skin. The compositions contain neat ionic liquids, optionally in combination with a drug to be delivered. In a preferred embodiment, the compositions increase transdermal transport of the drug to be delivered. In some embodiments, the compositions disrupt bacterial biofilms. This is particularly beneficial in the treatment of antibiotic resistant skin infections. In other embodiments, the compositions direct delivery within the skin. In still other embodiments, the compositions prevent transfer of substances through the stratum corneum. The disclosed compositions and methods can be tuned and modified such that they can be used to treat or prevent a variety of different diseases and disorders. | 2019-12-26 |
20190388546 | PROCESS FOR THE PREPARATION OF PEGYLATED DRUG-LINKERS AND INTERMEDIATES THEREOF - The present invention provides improved processes for the preparation of auristatin drug-linkers with a PEG unit, as well as intermediates thereof. | 2019-12-26 |
20190388547 | MULTIPLE OLIGONUCLEOTIDE MOIETIES ON PEPTIDE CARRIER - The present disclosure relates to antisense oligonucleotides (AONs), such as phosphorodiamidate morpholino oligonucleotides (PMOs). The present disclosure further relates to the conjugation of multiple PMOs to cationic cell penetrating peptides (CPPs) to enhance the uptake of PMOs into skeletal and cardiac muscle cells. | 2019-12-26 |
20190388548 | METHOD FOR PROVIDING OCULAR NEUROPROTECTION OR FOR PREVENTING, TREATING OR ALLEVIATING THE EFFECTS OF, AN OCULAR DISEASE ASSOCIATED WITH RETINAL GANGLION CELL DEATH - The present invention relates to a method for providing ocular neuroprotection or for preventing, treating or alleviating the effects of, an ocular disease associated with retinal ganglion cell death in a subject in need thereof, comprising administering to said subject an effective amount of a recombinant P-selectin immunoglobin G (P-sel-IgG) chimeric fusion protein, or a composition comprising the protein and a pharmaceutically acceptable adjuvant, vehicle, or carrier. | 2019-12-26 |
20190388549 | Targeted Protease Compositions and Uses Related Thereto - This disclosure relates to targeted protease compositions and uses related thereto. In certain embodiments, the disclosure relates to nanoparticles wherein a targeting molecule is linked to the nanoparticle and wherein a catalytic domain of a protease is linked to the nanoparticle. In certain embodiments, the targeting molecule and the catalytic domain are within a single polypeptide sequence. In certain embodiments, the targeting molecule binds a molecule more highly expressed on cancer cells then non-cancerous cells, and the nanoparticles disclosed herein are used for the treatment of cancer by further attaching an anti-cancer agent to the nanoparticle or incorporating an anticancer agent within the nanoparticle. | 2019-12-26 |
20190388550 | Compositions and Methods for Oral Delivery of Therapeutic Cargo - The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders. The present disclosure relates to a non-toxic mutant form of the | 2019-12-26 |
20190388551 | NUCLEIC ACID CONSTRUCTS AND METHODS OF USING THE SAME - Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed. | 2019-12-26 |
20190388552 | SELECTIVE REDUCTION OF CYSTEINE-ENGINEERED ANTIBODIES - The present invention relates to a process for the selective reduction of cysteine-engineered antibodies comprising reacting an antibody comprising one or more engineered cysteines at positions selected from HC40, HC41,HC42, HC89, HC152, HC153, HC155, HC171, LC40, LC41, LC165, and LC168 with a compound according to formula (I), (II), (III), (IV), (V), (VI) or (VII): (I) (II) (III) (IV) (V) (VI) (VII), and to a process for the preparation of antibody conjugates, including antibody-drug conjugates (ADCs). | 2019-12-26 |
20190388553 | ANTIBODY-DRUG CONJUGATE WITH A TUBULYSIN ANALOG WARHEAD HAVING A STABILIZED ACETATE GROUP IN THE TUV SUBUNIT - In antibody-drug conjugates having tubulysin analog as the warhead, according to formula (III) | 2019-12-26 |
20190388554 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF - A compound which is either A: | 2019-12-26 |
20190388555 | DI-SUBSTITUTED MALEIC AMIDE LINKER FOR ANTIBODY-DRUG CONJUGATING AND PREPARATION METHOD AND USE THEREOF - Provided in the present invention are a di-substituted maleic amide linker conjugated to an antibody and a preparation method and use thereof. In particular, the present invention conjugates a strongly cytotoxic active substance to a biomacromolecule through a class of new linkers. The class of linkers can selectively act simultaneously with disulphide chains, so as to greatly improve the substance homogeneity of a conjugate. The conjugate prepared by the linker of the present invention has a high inhibitory activity on a cell strain expressing the corresponding antigen. Also provided is a method for preparing the above-mentioned conjugate and the use. | 2019-12-26 |
20190388556 | SUBSTANCE AND METHOD FOR USING THE SUBSTANCE MENTIONED FOR MODULATING THE ACTIVITY OF AN AGENT IN AN ORGANISM - The invention relates to biomedicine and nanomedicine, and makes it possible to enhance the diagnostic or therapeutic efficiency of an agent administered to the organism. The invention can be used to enhance methods of diagnostics and therapy of various diseases due to a more effective (passive or active) delivery of the agent to cell-targets, improved pharmacokinetic parameters of the agent (circulation time), etc. The essence of the invention consists in a substance for enhancing the diagnostic or therapeutic efficiency of an agent administered to the organism, this substance comprising a component that, upon administration of the substance to the organism, enables elimination from the bloodstream by the reticuloendothelial system of at least the objects, which circulate in the bloodstream but do not represent artificially created nanoparticles or microparticles, or opsonins that non-specifically bind to said component, and said elimination of said objects causes blockade, at least partial, of the reticuloendothelial system. The technical result of application of the invention consists in creation of the method for blockade of the cells of reticuloendothelial system by means of administration of a small amount of a foreign substance or a safe biocompatible substance, and also the result consists in enhancement (boosting) of the blockade effect. | 2019-12-26 |
20190388557 | RAAV WITH CHEMICALLY MODIFIED CAPSID - The invention is directed to the field of gene therapy, i.e. gene delivery into target cells, tissue, organ and organism, and more particularly to gene delivery via viral vectors. The inventors showed that it is possible by chemical coupling to modulate the coupling of a ligand in the surface of the capsid of AAV, for example AAV2 and AAV3b. In particular, the present invention relates to a recombinant Adeno-Associated Virus (rAAV) vector particle having at least one primary amino group contained in the capsid proteins, chemically coupled with at least one ligand L, wherein coupling of said ligand L is implemented through a bond comprising a —CSNH— bond and an optionally substituted aromatic moiety. Particularly, the inventors tested the chemical coupling of mannose ligand on AAV2 for subretinally injection to rats. The present invention further relates to a method for chemically coupling an Adeno-Associated Virus (AAV) vector particle with at least one ligand L and to a Recombinant Adeno-Associated Virus (rAAV) vector particle obtained by said method as well as a pharmaceutical composition comprising it and their corresponding medical use. | 2019-12-26 |
20190388558 | KARTOGENIN DERIVATIVE-CONTAINING POLYMERIC MICELLE, HYALURONIC ACID HYDROGEL, METHOD FOR PRODUCING THE SAME, AND USE THEREOF - The present invention relates to a polymeric micelle including a kartogenin derivative, a hyaluronic acid hydrogel including the same, a method for producing the same, and a use thereof, and the polymeric micelle and the hyaluronic acid derivative hydrogel including the polymeric micelle slowly release kartogenin, and thus may be usefully used for the purpose of preventing or treating various cartilage disorder-related diseases such as degenerative arthritis because an effect of regenerating chondrocytes while protecting chondrocytes is excellent. | 2019-12-26 |
20190388559 | ENCAPSULATION OF METAL OXIDE NANOMATERIALS FOR CONTROLLED RELEASE AND TARGETED DELIVERY - The present invention is directed to micro and nanosized capsule compositions and methods of using and making the capsule compositions. The capsule compositions comprise an outer layer of lipids and/or polymers and inner contents comprising semiconductor nanoparticles. The nanoparticles are either metal oxides or quantum dots and will produce reactive oxygen species when irradiated with either electromagnetic radiation or ultrasound. The reactive oxygen species will degrade the outer layer of the capsule and cause the release of the contents, including the reactive oxygen species, into the local environment. The contents may optionally include cancer treating agent, water treating agents, antimicrobials, imaging and/or contracting agents. The outer layer may be further coated to protect it from environmental factors and/or be conjugated with a targeting molecule to increase delivery to a target. | 2019-12-26 |